Prostaglandin E2 receptor subtype 2 (EP2) null mice are protected against murine lung tumorigenesis

Anticancer Research

Volumn 26, Issue 4 B, 2006, Pages 2857-2861

  Keith, Robert L ^a,b   Geraci, Mark W ^b   Nana Sinkam, S Patrick ^b   Breyer, Richard M ^c   Hudish, Tyler M ^a   Meyer, Amy M ^b   Malkinson, Alvin M ^b   Dwyer Nield, Lori D ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic pulmonary inflammation; Downstream prostaglandin receptors; EP2; Two stage carcinogenesis

Indexed keywords

BUTYLCRESOL; PROSTAGLANDIN E RECEPTOR; 3 METHYLCHOLANTHRENE; PROSTAGLANDIN EP2 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL INFILTRATION; CHRONIC LUNG DISEASE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GROWTH RATE; INFLAMMATORY CELL; LUNG TUMOR; MALE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN DEFICIENCY; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; CELL GROWTH; CHEMICALLY INDUCED DISORDER; GENETICS; IMMUNOLOGY; LEUKOCYTE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BUTYLATED HYDROXYTOLUENE; CELL GROWTH PROCESSES; FEMALE; LEUKOCYTES; LUNG NEOPLASMS; MALE; METHYLCHOLANTHRENE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; RECEPTORS, PROSTAGLANDIN E;

EID: 33746710377     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 55: 10-30, 2005.
2. 2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate. J Exp Ther Oncol 4: 317-325, 2004.
3. 2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells. J Leukoc Biol 78: 555-564, 2005.
4. Eibl G, Bruemmer D, Okada Y, Duffy JP, Law RE, Reber HA and Hines OJ: PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun 306: 887-897, 2003.
5. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H and Dubinett SM: Non-small cell lung cancer cyclooxygenase-2- dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 58: 1208-1216, 1998.
6. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, Zhu L, Kronenberg M, Miller PW, Portanova J, Lee JC and Dubinett SM: Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164: 361-370, 2000.
7. 2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 277: 50828-50833, 2002.
8. 2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278: 35451-35457, 2003.
9. Thun MJ, Namboodiri MM and Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596, 1991.
10. Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, Piantadosi S, Garrett E, Geiman DE, Hubbard W, Offerhaus GJ and Hamilton SR: Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346: 1054-1059, 2002.
11. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, Ferrara CA, Yankelevitz DF, Subbaramaiah K, Pasmantier MW and Dannenberg AJ: Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 21: 2645-2650, 2003.
12. Csiki I, Morrow JD, Sandler A, Shyr Y, Oates J, Williams MK, Dang T, Carbone DP and Johnson DH: Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clin Cancer Res 11: 6634-6640, 2005.
13. Gasparini G, Meo S, Comella G, Stani SC, Mariani L, Gamucci T, Avallone A, Lo VS, Mansueto G, Bonginelli P, Gattuso D and Gion M: The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates. Cancer J 11: 209-216, 2005.
14. Nugent FW, Mertens WC, Graziano S, Levitan N, Collea R, Gajra A, Marshall J and McCann J: Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial. Lung Cancer 48: 267-273, 2005.
15. Kisley LR, Barrett BS, Dwyer-Nield LD, Bauer AK, Thompson DC and Malkinson AM: Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. Carcinogenesis 23: 1653-1660, 2002.
16. Keith RL, Miller YE, Hoshikawa Y, Moore MD, Gesell TL, Gao B, Malkinson AM, Golpon HA, Nemenoff RA and Geraci MW: Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res 62: 734-740, 2002.
17. Keith RL, Miller YE, Hudish TM, Girod CE, Sotto-Santiago S, Franklin WA, Nemenoff RA, March TH, Nana-Sinkam SP and Geraci MW: Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res 64: 5897-5904, 2004.
18. Dwyer-Nield L, Srebernak MC, Barrett BS, Ahn J, Cosper P, Meyer A, Kisley L, Bauer A, Thompson DC and Malkinson A: Cytokines differentially regulate the synthesis of prostanoid and nitric oxide mediators in tumorigenic vs. non-tumorigenic mouse lung epithelial cell lines. Carcinogenesis 26: 1196-1206, 2005.
19. Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA Jr, Johnson GL, Hirsch FR, Merrick DT, Franklin WA, Baron AE, Keith RL, Nemenoff RA, Malkinson AM and Geraci MW: Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 167: 1763-1775, 2005.
20. Breyer MD, Jacobson HR and Breyer RM: Functional and molecular aspects of renal prostaglandin receptors. J Am Soc Nephrol 7: 8-17, 1996.
21. 4 subtypes regulate B lymphocyte activation and differentiation to IgE-secreting cells. Adv Exp Med Biol 433: 153-157, 1997..
22. Rocca B, Spain LM, Pure E, Langenbach R, Patrono C and FitzGerald GA: Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest 105: 1469-1477, 1999.
23. Nataraj C, Thomas DW, Tilley SL, Nguyen MT, Mannon R, Koller BH and Coffman TM: Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J Clin Invest 108: 1229-1235, 2001.
24. Strong VE, Mackrell PJ, Concannon EM, Naama HA, Schaefer PA, Shaftan GW, Stapleton PP and Daly JM: Blocking prostaglandin E2 after trauma attenuates pro-inflammatory cytokines and improves survival. Shock 14: 374-379, 2000.
25. Hata AN and Breyer RM: Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 103: 147-166, 2004.
26. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Ushikubi F, Narumiya S, Sugimura T and Wakabayashi K: Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 59: 5093-5096, 1999.
27. Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T, Tani K, Kobayashi M, Maruyama T, Kobayashi K, Ohuchida S, Sugimoto Y, Narumiya S, Sugimura T and Wakabayashi K: Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 62: 28-32, 2002.
28. 2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. FEBS Lett 518: 154-158, 2002.
29. 3. Cancer Lett 214: 115-120, 2004.
30. 2 results in suppression of skin tumor development. Cancer Res 65: 9304-9311, 2005.
31. 2 receptor in immortalized human keratinocytes results in increased invasiveness and decreased paxillin expression. Am J Pathol 161: 2065-2078, 2002.
32. Sheller JR, Mitchell D, Meyrick B, Gates J and Breyer R: EP(2) receptor mediates bronchodilation by PGE(2) in mice. J Appl Physiol 88: 2214-2218, 2000.
33. White ES, Atrasz RG, Dickie EG, Aronoff DM, Stambolic V, Mak TW, Moore BB and Peters-Golden M: Prostaglandin E(2) inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activity. Am J Respir Cell Mol Biol 32: 135-141, 2005.
34. 2. J Immunol 174: 5644-5649, 2005.
35. 2 by PPARgamma ligands inhibits human lung carcinoma cell growth. Biochem Biophys Res Commun 314: 1093-1099, 2004.
36. Yang L, Yamagata N, Yadav R, Brandon S, Courtney RL, Morrow JD, Shyr Y, Boothby M, Joyce S, Carbone DP and Breyer RM: Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 111: 727-735, 2003.
37. Malkinson AM, Koski KM, Evans WA and Festing MF: Butylated hydroxytoluene exposure is necessary to induce lung tumors in BALB mice treated with 3-methylcholanthrene. Cancer Res 57: 2832-2834, 1997.
38. 2 receptor. Nat Med 5: 217-220, 1999.
39. Bauer AK, Dwyer-Nield LD, Hankin JA, Murphy RC and Malkinson AM: The lung tumor promoter, butylated hydroxytoluene (BHT), causes chronic inflammation in promotion-sensitive BALB/cByJ mice but not in promotion- resistant CXB4 mice. Toxicology 169: 1-15, 2001.
40. Bauer AK, Dwyer-Nield LD, Keil K, Koski K and Malkinson AM: Butylated hydroxytoluene (BHT) induction of pulmonary inflammation: a role in tumor promotion. Exp Lung Res 27: 197-216, 2001.
41. 2 in acute cutaneous inflammation. J Immunol 173: 1321-1326, 2004.
42. + T regulatory cell activities in lung cancer. Cancer Res 65: 5211-5220, 2005.
43. 2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310: 1504-1510, 2005.